KAKKIS EMIL D 1248093 Data last updated 2024-05-14 07:02:16 -0500 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-23 | 2023-10-19 | 4 | Kakkis Emil D | PRESIDENT & CEO | holding | 2263985.0 | 0 | 316.69 | 0.0 | By Emil Kakkis And Jenny Soriano Living Trust, Dated June 18, 200 | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | NA | 71.49 (RARE) | ||
| 2023-10-23 | 2023-10-19 | 2023-10-19 | 4 | Kakkis Emil D | PRESIDENT & CEO | acq | 47853.0 | 7.4 | 6.69 | 6.86 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code M | 647029.0 | 71.49 (RARE) |
| 2023-10-23 | 2023-10-19 | 2023-10-19 | 4 | Kakkis Emil D | PRESIDENT & CEO | dsp | 47853.0 | 7.39 | 6.69 | 33.52 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code S | 599743.0 | 71.49 (RARE) |
| 2024-01-02 | 2023-12-29 | 2023-12-29 | 4 | Kakkis Emil D | PRESIDENT & CEO | dsp | 30000.0 | 5.0 | 3.65 | 47.87 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code S | 569770.0 | 82.11 (RARE) |
| 2024-01-02 | 2023-12-29 | 4 | Kakkis Emil D | PRESIDENT & CEO | holding | 2263985.0 | 0 | 275.71 | 0.0 | By Emil Kakkis And Jenny Soriano Living Trust, Dated June 18, 200 | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | NA | 82.11 (RARE) | ||
| 2024-02-08 | 2024-02-07 | 2024-02-07 | 4 | Kakkis Emil D | PRESIDENT & CEO | dsp | 30000.0 | 5.27 | 3.65 | 45.0 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code S | 539770.0 | 82.11 (RARE) |
| 2024-02-08 | 2024-02-07 | 4 | Kakkis Emil D | PRESIDENT & CEO | holding | 2263985.0 | 0 | 275.71 | 0.0 | By Emil Kakkis And Jenny Soriano Living Trust, Dated June 18, 200 | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | NA | 82.11 (RARE) | ||
| 2024-03-05 | 2024-03-01 | 4 | Kakkis Emil D | PRESIDENT & CEO | holding | 2263985.0 | 0 | 275.71 | 0.0 | See Fn | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | NA | 82.11 (RARE) | ||
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Kakkis Emil D | PRESIDENT & CEO | acq | 41560.0 | 7.37 | 5.06 | 0.0 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code A | 563913.0
|
82.11 (RARE) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Kakkis Emil D | PRESIDENT & CEO | dsp | 17417.0 | 3.01 | 2.12 | 53.69 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code F | 560781.0 | 82.11 (RARE) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-23 | 2023-10-19 | 2023-10-19 | 4 | Kakkis Emil D | PRESIDENT & CEO | dsp | 47853.0 | 100.0 | 6.69 | 6.86 | Direct | Stock Option (Right To Buy) | ULTRAGENYX PHARMACEUTICAL INC. | code M | 0.0 | 71.49 (RARE) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Kakkis Emil D | PRESIDENT & CEO | acq | 70094.0 | 100.0 | 8.54 | 53.69 | Direct | Stock Option (Right To Buy) | ULTRAGENYX PHARMACEUTICAL INC. | code A | 70094.0 | 82.11 (RARE) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)